Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children? (Q37392869)

20 August 2017

Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children? (English)

1 reference

20 August 2017

1 reference

2

Saik Urien

0 references

Jean-Marc Tréluyer

12

object named as

Jean-Marc Tréluyer

0 references

Philippe Van de Perre

object named as

Philippe Van De Perre

11

0 references

Philippe Msellati

10

object named as

Philippe Msellati

1 reference

20 August 2017

Déborah Hirt

1

1 reference

20 August 2017

Saik Urien

2

1 reference

20 August 2017

Mathieu Olivier

3

1 reference

20 August 2017

Hélène Peyrière

4

1 reference

20 August 2017

Boubacar Nacro

5

1 reference

20 August 2017

Serge Diagbouga

6

1 reference

20 August 2017

Emmanuelle Zoure

7

1 reference

20 August 2017

François Rouet

8

1 reference

20 August 2017

Hervé Hien

9

1 reference

20 August 2017

Jean-Marc Tréluyer

12

1 reference

20 August 2017

language of work or name

English

0 references

publication date

27 July 2009

1 reference

Antimicrobial Agents and Chemotherapy

20 August 2017

1 reference

20 August 2017

53

1 reference

20 August 2017

10

1 reference

20 August 2017

4407-4413

1 reference

Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764212

Pharmacology considerations for antiretroviral therapy in human immunodeficiency virus (HIV)-infected children

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764212

Once‐a‐Day Highly Active Antiretroviral Therapy: A Systematic Review

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764212

Ways to fit a PK model with some data below the quantification limit

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764212

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764212

Impact of HIV-1 genetic diversity on plasma HIV-1 RNA Quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764212

Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764212

Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelines.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764212

Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764212

Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764212

A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764212

Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764212

The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764212

Performance analysis of a rapid HPLC determination with the solvent demixing extraction of HIV antiproteases and efavirenz in plasma

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764212

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764212

Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764212

A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764212

High Prevalence of Subtherapeutic Plasma Concentrations of Efavirenz in Children

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764212

Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients

3 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19635964

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1128/AAC.01594-08

1 reference

20 August 2017

1 reference

20 August 2017

PubMed publication ID

19635964

1 reference